Cell Viability Assays Research Report: By Product (Consumables, Instruments), by Cell Type (Human Cells, Microbial Cells, Animal cells), by Application (Stem Cell Research & Others), End-User (Pharma Biotech Companies & Others)– Forecast Till 2023
Market Research Future (MRFR) has published a report stating that the Cell viability Assays market Share is to expand at a CAGR of 9.2% during the forecast period of 2018-2023. Increasing incidences of individuals suffering from chronic diseases such as cancer and diabetes have induced high demand for technologically advanced diagnosis and treatment solutions in the healthcare sector. Rise in adoption of advanced technology in the healthcare sector and rise in prevalence of cancer and diabetes are majorly driving the growth of the global cell viability assays market. Increasing investments in research activities for the development of advanced healthcare solutions and high demand for effective treatment and diagnostic techniques are some other factors that are propelling the growth of the global cell viability assays market. However, low penetration of advanced technology and poor healthcare facilities in the underdeveloped regions are restraining the expansion of the global cell viability assays market during the forecast period.
The global cell viability assays market has been segmented on the basis of products, cell type, applications, and end-user. Based on products, the cell viability assays market has been segmented into consumables and instruments. Among these, the consumables segment has been sub-segmented into reagents, assay kits, and microplates. The assay kits sub-segment includes tetrazolium reduction assay kits, resazurin cell viability assays kits, calcein-Am cell viability assays kits and others. Furthermore, the tetrazolium reduction assay kits are classified into MIT assay kits and others. The instruments segment has been sub-segmented into automated cell counters, flow cytometers, spectrophotometers, and cell imaging and analysis systems.
Based on cell type, the cell viability assays market has been segmented into human cells, microbial cells, and animal cells. Based on applications, the cell viability assays market has been segmented into stem cell research, clinical and diagnostic applications, drug discovery and development, and others. Based on end-user, the cell viability assays market has been segmented into pharmaceutical and biotechnology companies, academic and research institutes, hospital and diagnostic laboratories, and others.
Browse Complete Report: https://www.marketresearchfuture.com/reports/cell-viability-assays-market-6391
The global cell viability assays market has been geographically segmented into four major regions such as the Americas, Asia Pacific, Europe, and the Middle East and Africa. The Americas is forecasted to dominate the global cell viability assays market owing to the rapid adoption of technologically advanced diagnosis and treatment procedures in the well-developed healthcare sector, increasing healthcare expenditure by the population and rise in prevalence of cancer and diabetes in this region.
The cell viability assays market in the Europe region is anticipated to expand at a significant growth rate owing to the increased research activities for the development of advanced techniques in the healthcare sector of this region. Increasing adoption of advanced technology in healthcare sector for stem cell, genomics and proteomics research activities propelling the growth of cell viability assays market in the Asia Pacific region. The Middle East and Africa region is projecting slow rate of expansion in the global market owing to the low penetration of advanced healthcare technologies in the underdeveloped areas of this region.
In September 2018, PharmaCyte Biotech, Inc., a clinical stage biotechnology company that focuses on developing targeted cellular therapies for treating diabetes and cancer by using its patented live-cell encapsulation technology, Cell-in-a-Box, has announced that it has completed the study to determine the best assay method for accurate determination of number of viable encapsulated cells at any given time, which will be used for treating locally advanced, non-metastatic, inoperable cancer.
The key player profiled by MRFR that are operating in the global cell viability assays market are Thermo Fisher Scientific, Merck KGaA, Bio-Rad Laboratories, GE Healthcare, Danaher Corporation, Becton Dickinson & Company, Promega Corporation, Biotium, Abcam plc, Creative Bioarray, Biotek Instruments, and PerkinElmer are some of the key players in the global cell Viability Assays market.